DCEBIO
Based on 1 Customer Validation
DCEBIO is a small/medium conductance calcium-activated potassium (SKCa/IKCa) channel opener and primary neuron signal blocker. It hyperpolarizes the membrane potential of C2C12 myoblasts by activating IKCa channels, thereby promoting myogenic differentiation. The specific biological activity of DCEBIO is manifested in increased myotube formation, enhanced myosin heavy chain II protein levels and myogenin mRNA levels. DCEBIO can be applied in the field of muscle research, especially in muscle-related degenerative diseases such as sarcopenia.
For research use only. We do not sell to patients.
- Purity: 99.25%
- CAS No.: 60563-36-2
- Formula: C9H8Cl2N2O
- Molecular Weight:231.08
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Biological Activity
Cl- secretion[1]
DCEBIO (10 μM; 4 days) significantly increases myotube formation, myosin heavy chain II protein expression levels, and myogenin mRNA expression levels in C2C12 myoblasts cultured in differentiation medium. DCEBIO also hyperpolarizes the membrane potential of C2C12 myoblasts in a concentration-dependent manner[1].
DCEBIO (5 μM) disruptes the vagal firing coding generated by serotonin when added to the intestinal serosa before serotonin perfusion in isolated mouse jejunal segments in vitro, as evidenced by changes in the mean interspike interval, burst duration, and gap duration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:C2C12 myoblasts
-
Concentration:10 μM
-
Incubation Time:4 days
-
Result:Significantly increased myotube formation. The fusion index of the DCEBIO-treated group (34.3 ± 1.9%) was significantly greater than that of the control group (21.1 ± 1.9%).
Significantly increased the protein expression level of skeletal muscle-specific myosin heavy chain II in DCEBIO-treated C2C12 myotubes compared with the control.
Chemical Information
-
CAS No. 60563-36-2
-
Appearance Solid
-
Molecular Weight 231.08
-
Formula C9H8Cl2N2O
-
Color White to light brown
-
SMILES
O=C1NC2=CC(Cl)=C(Cl)C=C2N1CC
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 50 mg/mL (216.38 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.82 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Tanaka S, et al. DCEBIO facilitates myogenic differentiation via intermediate conductance Ca2+ activated K+ channel activation in C2C12 myoblasts. J Pharmacol Sci. 2017 Apr;133(4):276-279. [Content Brief]
[2]. West CL, et al. Identification of SSRI-evoked antidepressant sensory signals by decoding vagus nerve activity. Sci Rep. 2021 Oct 26;11(1):21130. [Content Brief]
[3]. Iseki Y, et al. Opening of Intermediate Conductance Ca2+-Activated K+ Channels in C2C12 Skeletal Muscle Cells Increases the Myotube Diameter via the Akt/Mammalian Target of Rapamycin Pathway. J Pharmacol Exp Ther. 2021 Mar;376(3):454-462. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.3275 mL | 21.6375 mL | 43.2751 mL | 108.1876 mL |
| 5 mM | 0.8655 mL | 4.3275 mL | 8.6550 mL | 21.6375 mL | |
| 10 mM | 0.4328 mL | 2.1638 mL | 4.3275 mL | 10.8188 mL | |
| 15 mM | 0.2885 mL | 1.4425 mL | 2.8850 mL | 7.2125 mL | |
| 20 mM | 0.2164 mL | 1.0819 mL | 2.1638 mL | 5.4094 mL | |
| 25 mM | 0.1731 mL | 0.8655 mL | 1.7310 mL | 4.3275 mL | |
| 30 mM | 0.1443 mL | 0.7213 mL | 1.4425 mL | 3.6063 mL | |
| 40 mM | 0.1082 mL | 0.5409 mL | 1.0819 mL | 2.7047 mL | |
| 50 mM | 0.0866 mL | 0.4328 mL | 0.8655 mL | 2.1638 mL | |
| 60 mM | 0.0721 mL | 0.3606 mL | 0.7213 mL | 1.8031 mL | |
| 80 mM | 0.0541 mL | 0.2705 mL | 0.5409 mL | 1.3523 mL | |
| 100 mM | 0.0433 mL | 0.2164 mL | 0.4328 mL | 1.0819 mL |